News 2021-06-24
CfPC Announces Program of 2021 Pharmaceutical Crystallization Summit(Reproduced)
The Center for Pharma Crystallization (CfPC) at J-Star Research, Inc., a US based subsidiary of Porton Pharma Solutions, is pleased to announce the program of the 2nd annual Pharmaceutical Crystallization Summit, to be held on October 14 and 15, 2021, jointly with our partners XtalPi, BlazeMetrics, and Technobis.
The 2-day event includes 4 sessions, with 12 keynote presentations by leading industrial and academic experts, and 3 topical panel discussions moderated by SMEs from the pharma industry. See topical and speaker details at www.pharmaceuticalcrystallizationsummit.com.
“Serving the patients with the right DP (drug product) in the fastest way possible requires scientists on the API (active pharmaceutical ingredient) side, and DP side to work hand in hand, not in isolation. The speakers at this conference will demonstrate how this kind of collaboration can lead to experimental and theoretical tools to better understand the fundamentals of APIs, their interaction with excipients, API crystallization and formulation processes” said Dr. San Kiang, CTO of Porton, Chairman of the Pharmaceutical Crystallization Summit.
“I’m really excited about this year’s Summit. The superb program that is in place will offer in-depth scientific and technical discussions on crystallization technologies, geared towards overcoming hurdles in new drug development programs,” said Dr. Jian Wang, SVP, CfPC at J-Star Research. “I look forward to meeting both old and new friends in the pharma crystallization field in October.”
About J-Star Research, Inc.
Founded in 1996, J-STAR Research, Inc. is a leading contract research organization serving as an outsourcing partner for the pharmaceutical and biotechnology industries. While high quality services in synthetic chemistry and process research continue to be at J-Star’s foundation, the company has steadily added and continues to expand in the areas of QC/QA and GMP Processing, Crystallization R&D (Solid Form & Pre-Formulation Studies, Crystallization Process Development & Particle Engineering, etc.), Catalysis Screening & Enabling Technologies, HPAPI, Impurity Isolation & Structural Elucidation, and Drug Product Development. The Center for Pharma Crystallization (CfPC) was found in 2014, has about 50 scientists (based in New Jersey and Shanghai) with total 164 years of R&D experiences working in large pharma companies and 86 years of experiences serving global clients in CROs.
About Porton Pharma Solutions
With over 2,800 customer-centric employees, operations and commercial offices across the US, EU and China, Porton Pharma Solutions provides global pharmaceutical companies with innovative, reliable and end-to-end process R&D and manufacturing services across small molecule APIs, dosage forms and biologics.
About XtalPi
XtalPi is a pharmaceutical technology company reinventing the industry’s approach to drug research and development with its Intelligent Digital Drug Discovery and Development (ID4) platform, which provides accurate predictions on the physiochemical and pharmaceutical properties of small-molecule candidates for drug design, solid-form selection, and other critical aspects of drug development. Founded in 2014 by a group of quantum physicists at MIT, XtalPi has built an elite team with expertise in physics, chemistry, pharmaceutical R&D, and algorithm design, helping it to establish strategic partnerships with top international pharmaceutical companies.
About BlazeMetrics
BlazeMetrics offers a single probe that integrates multiple best-in-class technology including: Microscopy, Particle Size & Count through vastly improved CLD, HDR Turbidity, and the optional addition of 532 &/or 785nm excited Raman, and/or Particle Polarization. The Blaze Team gathered in 1991 to design, develop, & pioneer the application of In-Process CLD based Particle Size & Count and In-Process Microscopy tools. The last versions designed in 2009 are still sold, thousands of them still in use today. In 2014 Blaze decided to bring industry the next generation of enabling & cost-effective PAT. Blaze advanced technology speeds process development through enabling better, simpler (easier to understand), and faster process understanding for drug substance and drug product teams of both small and large molecules.
About Technobis Crystallization Systems
Technobis Crystallization Systems is a world leading technology provider for solid-state research, process development and formulation. Since 2005, platforms for accelerating crystallisation research have been successfully developed and installed in nearly every pharmaceutical research lab in the world. With more than 500 units in the field, a large community of scientists have been enabled to make a significant contribution to the accelerated development of new pharmaceuticals.
The 2-day event includes 4 sessions, with 12 keynote presentations by leading industrial and academic experts, and 3 topical panel discussions moderated by SMEs from the pharma industry. See topical and speaker details at www.pharmaceuticalcrystallizationsummit.com.
“Serving the patients with the right DP (drug product) in the fastest way possible requires scientists on the API (active pharmaceutical ingredient) side, and DP side to work hand in hand, not in isolation. The speakers at this conference will demonstrate how this kind of collaboration can lead to experimental and theoretical tools to better understand the fundamentals of APIs, their interaction with excipients, API crystallization and formulation processes” said Dr. San Kiang, CTO of Porton, Chairman of the Pharmaceutical Crystallization Summit.
“I’m really excited about this year’s Summit. The superb program that is in place will offer in-depth scientific and technical discussions on crystallization technologies, geared towards overcoming hurdles in new drug development programs,” said Dr. Jian Wang, SVP, CfPC at J-Star Research. “I look forward to meeting both old and new friends in the pharma crystallization field in October.”
About J-Star Research, Inc.
Founded in 1996, J-STAR Research, Inc. is a leading contract research organization serving as an outsourcing partner for the pharmaceutical and biotechnology industries. While high quality services in synthetic chemistry and process research continue to be at J-Star’s foundation, the company has steadily added and continues to expand in the areas of QC/QA and GMP Processing, Crystallization R&D (Solid Form & Pre-Formulation Studies, Crystallization Process Development & Particle Engineering, etc.), Catalysis Screening & Enabling Technologies, HPAPI, Impurity Isolation & Structural Elucidation, and Drug Product Development. The Center for Pharma Crystallization (CfPC) was found in 2014, has about 50 scientists (based in New Jersey and Shanghai) with total 164 years of R&D experiences working in large pharma companies and 86 years of experiences serving global clients in CROs.
About Porton Pharma Solutions
With over 2,800 customer-centric employees, operations and commercial offices across the US, EU and China, Porton Pharma Solutions provides global pharmaceutical companies with innovative, reliable and end-to-end process R&D and manufacturing services across small molecule APIs, dosage forms and biologics.
About XtalPi
XtalPi is a pharmaceutical technology company reinventing the industry’s approach to drug research and development with its Intelligent Digital Drug Discovery and Development (ID4) platform, which provides accurate predictions on the physiochemical and pharmaceutical properties of small-molecule candidates for drug design, solid-form selection, and other critical aspects of drug development. Founded in 2014 by a group of quantum physicists at MIT, XtalPi has built an elite team with expertise in physics, chemistry, pharmaceutical R&D, and algorithm design, helping it to establish strategic partnerships with top international pharmaceutical companies.
About BlazeMetrics
BlazeMetrics offers a single probe that integrates multiple best-in-class technology including: Microscopy, Particle Size & Count through vastly improved CLD, HDR Turbidity, and the optional addition of 532 &/or 785nm excited Raman, and/or Particle Polarization. The Blaze Team gathered in 1991 to design, develop, & pioneer the application of In-Process CLD based Particle Size & Count and In-Process Microscopy tools. The last versions designed in 2009 are still sold, thousands of them still in use today. In 2014 Blaze decided to bring industry the next generation of enabling & cost-effective PAT. Blaze advanced technology speeds process development through enabling better, simpler (easier to understand), and faster process understanding for drug substance and drug product teams of both small and large molecules.
About Technobis Crystallization Systems
Technobis Crystallization Systems is a world leading technology provider for solid-state research, process development and formulation. Since 2005, platforms for accelerating crystallisation research have been successfully developed and installed in nearly every pharmaceutical research lab in the world. With more than 500 units in the field, a large community of scientists have been enabled to make a significant contribution to the accelerated development of new pharmaceuticals.
Others
More
News 2024-10-31
Milestone | Comprehensive Enhancement of GMP Manufacturing Capacity and New Modality Service Capabilities at Porton Fengxian, Shanghai
Recently, Porton Pharma has achieved a significant capacity breakthrough at its GMP manufacturing facility in Fengxian, Shanghai, China, further enhancing its production capabilities and technological strength in new modality areas such as peptide and oligonucleotide drugs. This upgrade represents an important step in Porton's commitment to becoming a leading global CDMO company.
News 2024-10-24
Porton Pharma Solutions Signed Strategic Partnership with Shanghai InnoStar
On October 24, 2024, Porton Pharma SolutionsLtd. ("Porton") announced a strategic partnership with Shanghai InnoStar Bio-tech Co., Ltd. ("InnoStar") in Shanghai. The distinguished signing ceremony was attended by Mr. Ju Nianfeng, Chairman and CEO of Porton; Dr. Chang Yan, President of InnoStar; Ms. Pi Wei, Deputy General Manager of Porton; Ms. Fan Meng, Deputy General Manager of the Sales & Marketing Center, Dr. Fang Xin, Senior Director of Non-clinicalPharmacology BU at InnoStar, and Ms. Zhao Jie, Marketing Associate Director at InnoStar.
